Shots:
- BMS to acquire all the outstanding shares of MyoKardia’s common stock for $225.00/ share in cash, making a total deal value of ~$13.1B. The transaction is expected to be close in Q4’20
- The acquisition will foster BMS’ CV portfolio with the addition of MyoKardia’s mavacamten. BMS expects to explore mavacamten in additional indications, including non-obstructive HCM and will develop MyoKardia’s two clinical-stage therapies, danicamtiv (formerly MYK-491) and MYK-224
- Mavacamten is a potential first-in-class therapy with compelling data in the treatment of patients with symptomatic obstructive HCM. The NDA submission of the therapy is based on the EXPLORER-HCM study, which is expected to be submitted to the US FDA in the Q1’21
Click here to read full press release/ article | Ref: BMS | Image: MyoKardia
The post BMS to Acquire MyoKardia for ~.1B first appeared on PharmaShots.
